Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric L Simpson

Showing results (121-130 of 314) with videos related to

Pageof 32
Sort By:
Plos One|August 4, 2011
Eosinophils increase neuron branching in human and murine skin and in vitroErin L Foster, Eric L Simpson, Lorna J Fredrikson, et al.
JAMA Dermatology|February 27, 2020
Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis: A Phase 2b Randomized Clinical TrialEmma Guttman-Yassky, Andrew Blauvelt, Lawrence F Eichenfield, et al.
JAMA Dermatology|February 11, 2026
Development of a Patient Decision Aid for Atopic Dermatitis Systemic Treatments in AdultsRobyn Okereke, Wenelia Baghoomian, Rachel R Dunlap, et al.
The Journal of Dermatological Treatment|September 11, 2023
Disease burden among patients with atopic dermatitis treated with systemic therapy for 4-12 months: results from the CorEvitas Atopic Dermatitis RegistryJonathan I Silverberg, Evangeline Pierce, Meghan Feely, et al.
Dermatology and Therapy|July 28, 2025
Clinically Meaningful Improvements in Adolescents with Moderate-to-Severe Atopic Dermatitis Treated with Tralokinumab who did not Achieve Clear or Almost Clear Skin at Week 16Amy S Paller, Andrew Blauvelt, Weily Soong, et al.
Advances in Therapy|January 7, 2024
Summary of Research: An Anti-OX40 Antibody to Treat Moderate-to-Severe Atopic Dermatitis: A Multicentre, Double-Blind, Placebo-Controlled Phase 2b StudyEmma Guttman-Yassky, Eric L Simpson, Kristian Reich, et al.
Lancet (London, England)|November 18, 2023
Efficacy of rocatinlimab for moderate-to-severe atopic dermatitis - Authors' replyEmma Guttman-Yassky, Eric L Simpson, Kristian Reich, et al.
Pediatric Dermatology|September 8, 2011
Do early skin care practices alter the risk of atopic dermatitis? A case-control studyMarla E Rendell, Shahana F Baig-Lewis, Trista M Berry, et al.
Advances in Therapy|February 19, 2025
Onset and Long-Term Maintenance of Optimal Itch Response in Adult Patients with Moderate-to-Severe Atopic Dermatitis Treated with Dupilumab: Post Hoc Analysis from Two Phase 3 TrialsSonja Ständer, Gil Yosipovitch, Eric L Simpson, et al.
Journal of the American Academy of Dermatology|January 17, 2015
A systematic review of topical corticosteroid withdrawal ("steroid addiction") in patients with atopic dermatitis and other dermatosesTamar Hajar, Yael A Leshem, Jon M Hanifin, et al.
Pageof 32

Showing results (121-130 of 314) with videos related to

Sort By:
Pageof 32
Plos One|August 4, 2011
Eosinophils increase neuron branching in human and murine skin and in vitroErin L Foster, Eric L Simpson, Lorna J Fredrikson, et al.
JAMA Dermatology|February 27, 2020
Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis: A Phase 2b Randomized Clinical TrialEmma Guttman-Yassky, Andrew Blauvelt, Lawrence F Eichenfield, et al.
JAMA Dermatology|February 11, 2026
Development of a Patient Decision Aid for Atopic Dermatitis Systemic Treatments in AdultsRobyn Okereke, Wenelia Baghoomian, Rachel R Dunlap, et al.
The Journal of Dermatological Treatment|September 11, 2023
Disease burden among patients with atopic dermatitis treated with systemic therapy for 4-12 months: results from the CorEvitas Atopic Dermatitis RegistryJonathan I Silverberg, Evangeline Pierce, Meghan Feely, et al.
Dermatology and Therapy|July 28, 2025
Clinically Meaningful Improvements in Adolescents with Moderate-to-Severe Atopic Dermatitis Treated with Tralokinumab who did not Achieve Clear or Almost Clear Skin at Week 16Amy S Paller, Andrew Blauvelt, Weily Soong, et al.
Advances in Therapy|January 7, 2024
Summary of Research: An Anti-OX40 Antibody to Treat Moderate-to-Severe Atopic Dermatitis: A Multicentre, Double-Blind, Placebo-Controlled Phase 2b StudyEmma Guttman-Yassky, Eric L Simpson, Kristian Reich, et al.
Lancet (London, England)|November 18, 2023
Efficacy of rocatinlimab for moderate-to-severe atopic dermatitis - Authors' replyEmma Guttman-Yassky, Eric L Simpson, Kristian Reich, et al.
Pediatric Dermatology|September 8, 2011
Do early skin care practices alter the risk of atopic dermatitis? A case-control studyMarla E Rendell, Shahana F Baig-Lewis, Trista M Berry, et al.
Advances in Therapy|February 19, 2025
Onset and Long-Term Maintenance of Optimal Itch Response in Adult Patients with Moderate-to-Severe Atopic Dermatitis Treated with Dupilumab: Post Hoc Analysis from Two Phase 3 TrialsSonja Ständer, Gil Yosipovitch, Eric L Simpson, et al.
Journal of the American Academy of Dermatology|January 17, 2015
A systematic review of topical corticosteroid withdrawal ("steroid addiction") in patients with atopic dermatitis and other dermatosesTamar Hajar, Yael A Leshem, Jon M Hanifin, et al.
Pageof 32